세계의 신경혈관 혈전 제거 디바이스/뇌혈전 제거 디바이스 시장 규모는 2024년에 8억 4,970만 달러로, 2032년까지 14억 3,478만 달러에 달할 것으로 예측되며, 2025-2032년의 예측 기간에 CAGR로 6.88%의 성장이 전망됩니다. 신경질환, 특히 뇌졸중의 부담 증가로 신경혈관 혈전제거장치 시장이 크게 성장하고 있습니다. 이와 동시에 고혈압, 당뇨병, 비만 증가는 뇌졸중 및 기타 신경 장애의 위험을 더욱 악화시키고 있습니다. 이러한 상태는 뇌졸중의 확립된 위험 요소이며, 급성 허혈성 사건의 높은 발생률로 이어져 혈전 제거 장치에 대한 수요가 증가하고 있습니다. 그러나 기계식 혈전 제거 장치에 대한 인식과 채택이 증가함에 따라 시장이 더욱 활성화되고 있습니다. 또한 시장의 주요 기업은 혁신적인 신경혈관 혈전 제거 장치/뇌혈전 제거 장치를 도입하기 위한 연구개발에 지속적으로 투자하고 있으며, 파트너쉽 및 공동연구, 제품 출시 및 승인 증가로 인해 2025-2032년의 예측 기간 중 시장은 계속해서 역동적이고 혁신적일 것으로 예측됩니다. 될 것입니다.
신경혈관 혈전제거장치/뇌혈전제거장치 시장 역학
British Heart Foundation(2025)이 제공한 최신 데이터에 따르면 약 4,600만 명의 여성과 약 4,800만 명의 남성이 전 뇌졸중 환자였다고 합니다.
또한 World Stroke Organization(2025)의 최신 데이터에 따르면 매년 약 1,220만 명이 새롭게 뇌졸중을 앓고 있습니다. 전 세계에서 26세 이상 인구 4명 중 1명이 평생 동안 뇌졸중을 겪습니다.
뇌졸중 환자 수가 증가함에 따라 병원과 전문 치료 센터에서는 혈류를 회복시켜 생명을 살리는 솔루션으로 이러한 장치의 채택이 증가하고 있습니다. 뇌혈관을 막고 있는 혈전을 제거하도록 설계된 신경혈관 혈전 제거 장치는 뇌손상을 최소화하고 환자의 예후를 개선하기 위해 신속한 개입이 필수적인 급성 허혈성 뇌졸중 관리에 있으며, 매우 중요한 역할을 하고 있습니다. 그 결과, 뇌졸중 환자의 급격한 증가는 전체 신경혈관 혈전 제거 장치 시장의 성장을 가속하고, 이러한 장치가 주요 의료 문제를 해결하는 데 있으며, 중요한 역할을 하고 있음을 강조하고 있습니다.
또한 세계보건기구(WHO)(2024)가 제공한 데이터와 통계에 따르면 2022년 전 세계 8명 중 1명이 비만증을 앓고 있는 것으로 나타났습니다. 약 25억 명의 18세 이상 성인이 과체중이며, 그 중 8억 9,000만 명이 비만증을 앓고 있습니다. 18세 이상 성인 중 43%가 과체중, 16%가 비만증을 앓고 있는 것으로 나타났습니다. 또한 2022년 5세 미만 어린이 중 3,700만 명이 과체중입니다. 과체중 유병률은 어린이와 청소년의 과체중 유병률도 두드러지는데, 5-19세 중 3.9억 명 이상이 과체중이며, 그 중 1.6억 명은 비만증을 앓고 있었습니다.
비만은 혈전이 뇌혈관을 막아서 발생하는 허혈성 뇌졸중 등 여러 혈관질환의 위험인자로 알려져 있습니다. 전 세계에서 비만율이 증가함에 따라 뇌졸중 및 기타 관련 합병증 발병률도 증가하고 있습니다. 이러한 환자 수 증가는 뇌에서 혈전을 제거하고 정상적인 혈류를 회복시키는 데 사용되는 신경혈관 혈전 제거 장치에 대한 수요를 촉진하여 전체 시장을 확대시키고 있습니다.
또한 신경혈관 혈전 제거 장치/뇌혈전 제거 장치 시장에서의 성공적인 개발 활동은 전 세계 시장 전체를 더욱 촉진할 것입니다. 예를 들어 2025년 4월, 의료기기 및 체외 진단 기술을 의료 산업에 제공하는 선도적인 공급업체인 서모딕스(Surmodics, Inc.)는 Pounce(TM) 스위트에 추가된 Pounce(TM) XL 혈전제거 시스템(Pounce(TM) XL Thrombectomy System)의 출시를 발표했습니다. 이 시스템은 말초동맥에서 급성 또는 만성 혈전을 신속하게 혈관 내로 제거할 수 있도록 설계되어 혈관 중재시술 분야의 포트폴리오는 더욱 강화되었습니다.
따라서 위의 요인들은 예측 기간 중 신경혈관 혈전 제거 장치/뇌 혈전 제거 장치 시장을 촉진할 가능성이 높습니다.
그러나 혈관 천공, 색전증, 주변 뇌조직 손상 등의 합병증 위험과 제품 승인에 대한 엄격한 규제 우려로 인해 신경혈관 혈전제거장치/뇌혈전제거장치의 미래 시장을 저해할 수 있습니다.
세계의 신경혈관 혈전 제거 디바이스/뇌혈전 제거 디바이스 시장에 대해 조사분석했으며, 시장 규모와 예측, 과거 3년 제품/기술개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공하고 있습니다.
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising burden of neurological disorders such as stroke, increase in cases of hypertension, diabetes, obesity, growing awareness and adoption of mechanical thrombectomy, and increase in product launches and approvals by key market players across the globe.
The neurovascular thrombectomy devices/neurothrombectomy devices market was valued at USD 849.70 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 1,434.78 million by 2032. The rising burden of neurological disorders, particularly stroke, is significantly boosting the market for neurovascular thrombectomy devices as these are the medical instruments used to remove blood clots from the blood vessels in the brain. Concurrent with this, the rise in cases of hypertension, diabetes, and obesity further exacerbates the risk of stroke and other neurological disorders. These conditions are well-established risk factors for stroke, leading to a higher incidence of acute ischemic events and, consequently, an increased demand for thrombectomy devices. However, the growing awareness and adoption of mechanical thrombectomy devices have further boosted the market. Furthermore, key market players continuously investing in research and development to introduce innovative neurovascular thrombectomy devices/neurothrombectomy devices, increased partnerships and collaborations, product launches, and approvals ensure that the market remains dynamic and innovative, during the forecast period from 2025 to 2032.
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market Dynamics:
According to the recent data provided by the British Heart Foundation (2025), around 46 million women and 48 million men were stroke survivors.
Additionally, as per the latest data provided by the World Stroke Organization (2025), approximately, 12.2 million new strokes occur each year. Globally, one in four people over age 25 will have a stroke in their lifetime.
The escalating number of stroke cases leads to greater adoption of these devices in hospitals and specialized treatment centers, as they offer a life-saving solution for restoring blood flow. Neurovascular thrombectomy devices, which are designed to remove clots obstructing brain blood vessels, become crucial in managing acute ischemic stroke, a condition where rapid intervention is essential to minimize brain damage and improve patient outcomes. As a result, the surge in stroke cases drives the overall growth of the neurovascular thrombectomy device market, highlighting the critical role these devices play in addressing a major healthcare challenge.
Additionally, as per the data and stats provided by the World Health Organization (2024), in 2022, 1 in 8 people worldwide were living with obesity. Approximately, 2.5 billion adults aged 18 years and older were overweight, with 890 million of them living with obesity. Among adults aged 18 years and over, 43% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight in 2022. The prevalence of overweight was also significant among older children and adolescents, with over 390 million individuals aged 5-19 years being overweight, including 160 million who were living with obesity.
Obesity is a well-established risk factor for several vascular diseases, including ischemic stroke, which occurs when a blood clot obstructs a blood vessel in the brain. As the global obesity rates rise, there is a corresponding increase in the incidence of stroke and other related complications. This growing patient population drives demand for neurovascular thrombectomy devices, which are used to remove blood clots from the brain and restore normal blood flow thereby escalating the overall market.
Furthermore, the successful developmental activities in the neurovascular thrombectomy devices/neurothrombectomy devices market further boost the overall market across the globe. For instance, in April 2025, Surmodics, Inc., a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, announced the commercial launch of the Pounce(TM) XL Thrombectomy System, an advanced addition to its Pounce(TM) suite. The system was designed to enable rapid endovascular removal of acute or chronic thrombus from peripheral arteries, further strengthening the company's portfolio in vascular intervention.
Thus, the factors mentioned above are likely to boost the market of neurovascular thrombectomy devices/neurothrombectomy devices during the forecasted period.
However, the risk of complications such as vessel perforation, embolism, or damage to surrounding brain tissue and stringent regulatory concerns for product approval may hinder the future market of neurovascular thrombectomy devices/neurothrombectomy devices.
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market Segment Analysis:
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the neurovascular thrombectomy devices/neurothrombectomy devices market, clot retrievers are projected to hold a considerable market share in 2024. Clot retrievers are significantly boosting the overall market of neurovascular thrombectomy devices by revolutionizing the treatment of ischemic strokes. These devices, designed to mechanically remove blood clots from the brain's blood vessels, have enhanced the efficacy of thrombectomy procedures. Their advanced design and functionality enable more effective and reliable clot retrieval, which improves patient outcomes and increases the likelihood of complete recanalization of obstructed vessels. This has led to a broader adoption of thrombectomy as a standard treatment for acute ischemic stroke, thereby driving demand for these devices. The success of clot retrievers has also spurred innovation, leading to the development of newer, more sophisticated models with improved performance characteristics.
Additionally, clinical studies demonstrating the benefits of clot retrievers in reducing disability and mortality have increased their acceptance among healthcare professionals, further contributing to market growth. As more hospitals and stroke centers adopt these technologies, the market for neurovascular thrombectomy devices expands, driven by the increased emphasis on timely and effective stroke intervention.
This growth is also supported by ongoing research and development efforts, and other product development activities across the globe which continue to refine and enhance clot retrieval technologies, ensuring their continued relevance and effectiveness in stroke care. For instance, in June 2023, Innova Vascular received FDA clearance for two new thrombectomy devices Laguna Clot Retriever(TM) System and the Malibu Aspiration Catheter(TM) System. This system is indicated for non-surgical removal of emboli or thrombi, and/or infusing, injecting, or aspirating fluids into or from blood vessels in the peripheral vasculature.
Therefore, owing to the above-mentioned factors, the clot retriever category is expected to generate considerable revenue thereby pushing the overall growth of the global neurovascular thrombectomy devices/neurothrombectomy devices market during the forecast period.
North America is expected to dominate the overall neurovascular thrombectomy devices/neurothrombectomy devices market:
North America is expected to account for the highest proportion of the neurovascular thrombectomy devices/neurothrombectomy devices market in 2024, out of all regions. This can be ascribed to the increasing prevalence of stroke, obesity, hypertension, diabetes, and others, increased government initiatives coupled with increased awareness programs for neurovascular disease, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of neurovascular thrombectomy devices/neurothrombectomy devices.
According, to the latest data provided by the Centre for Disease Control and Prevention (2024), in the United States, a stroke occurs every 40 seconds, with more than 795,000 people experiencing a stroke annually. Of these, approximately 610,000 were first or new strokes, while around 185,000, or nearly 1 in 4, involved individuals had a previous stroke. Ischemic strokes, which result from blocked blood flow to the brain, accounted for about 87% of all stroke cases.
Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), nearly half of the adults in the United States, totaling 116 million, had hypertension, with the majority 92.1 million having their condition not under control.
Furthermore, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately, 38.4 million people of all ages, representing 11.6% of the U.S. population, had diabetes.
Diabetes and hypertension are major risk factors for stroke, leading to an increased demand for effective treatments to manage and mitigate these risks. Neurovascular thrombectomy devices, which are used to remove blood clots from the brain's blood vessels, become increasingly critical as the incidence of stroke rises. This growing demand for thrombectomy procedures drives the market for these devices, as healthcare providers seek advanced tools to enhance patient outcomes and reduce the impact of strokes. Consequently, the prevalence of diabetes and hypertension directly contributes to the market expansion of neurovascular thrombectomy devices across the region.
Moreover, the increase in product development activities and ongoing research and development further escalates the market of neurovascular thrombectomy devices/neurothrombectomy devices across the region. For instance, in February 2024, Innova Vascular announced the successful early commercial use of Laguna Thrombectomy System(TM) in patients.
Therefore, the above-mentioned factors are expected to bolster the growth of the neurovascular thrombectomy devices/neurothrombectomy devices market in North America during the forecast period.
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market Key Players:
Some of the key market players operating in the neurovascular thrombectomy devices/neurothrombectomy devices market include Stryker, Penumbra, Inc., Vesalio, LLC., Acandis GmbH, Rapid Medical, Johnson & Johnson Services Inc., Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroVention Inc., phenox GmbH, Biomedical Solutions Inc., Ceretrieve Ltd., Anaconda Biomed SL, Genesis Medtech., Innova Vascular, and others.
Recent Developmental Activities in the Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market:
Key takeaways from the neurovascular thrombectomy devices/neurothrombectomy devices market report study:
Target audience who can benefit from this neurovascular thrombectomy devices/neurothrombectomy devices market report study:
Frequently Asked Questions for the Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market: